Turner Construction Company announced that Agilent Technologies selected the company to build a USD 725 million facility to produce active pharmaceutical ingredients in Frederick in Colorado.The 200,000 square foot project increases Agilent’s capacity to meet demand for the company’s synthetic oligonucleotides, which help treat cancer, cardiovascular disease, and other rare diseases. The project will be built in accordance with Process Safety Management standards.The project is scheduled for completion in 2026.
Turner Construction Company announced that Agilent Technologies selected the company to build a USD 725 million facility to produce active pharmaceutical ingredients in Frederick in Colorado.The 200,000 square foot project increases Agilent’s capacity to meet demand for the company’s synthetic oligonucleotides, which help treat cancer, cardiovascular disease, and other rare diseases. The project will be built in accordance with Process Safety Management standards.The project is scheduled for completion in 2026.
